Diabetes - Pipeline Insight, 2026

DelveInsight’s, “Diabetes - Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Diabetes: Understanding

Diabetes: Overview

Diabetes mellitus is a chronic metabolic disorder characterized by abnormally elevated levels of blood glucose (hyperglycemia) resulting from defects in insulin secretion, insulin action, or both. It comprises several subtypes, with type 1 diabetes arising from autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency, and type 2 diabetes primarily associated with insulin resistance and relative insulin deficiency. The condition reflects a disruption in the normal balance between insulin and glucagon, which are essential for maintaining glucose homeostasis. Over time, persistent hyperglycemia can lead to serious complications affecting multiple organs, making diabetes one of the most prevalent and significant global health challenges. The pathophysiology of diabetes mellitus involves abnormalities in insulin production, insulin function, or both, which result in sustained high blood glucose levels. In type 1 diabetes, the immune system destroys pancreatic β-cells, causing a complete lack of insulin. In contrast, type 2 diabetes is characterized by insulin resistance, often linked to obesity and inflammatory factors, along with a gradual reduction in insulin secretion. Persistent hyperglycemia further impairs β-cell function, creating a cycle that worsens metabolic control. Increased glucagon levels also contribute by stimulating excess glucose production in the liver. Over time, prolonged high glucose levels lead to the glycation of proteins and lipids, damaging small blood vessels in organs such as the eyes, kidneys, and nerves, and contributing to the development of diabetes-related complications.

The signs and symptoms of diabetes can vary depending on the type and severity of the condition but generally include increased thirst and frequent urination, as the body tries to flush out excess glucose from the blood. Other common symptoms are extreme hunger, unexpected weight loss, fatigue, and blurred vision due to fluctuating blood sugar levels. Slow-healing sores, frequent infections, and tingling or numbness in the hands and feet are also prevalent, particularly in Type 2 diabetes, indicating nerve damage. The treatment of diabetes focuses on managing blood sugar levels through a combination of lifestyle changes, medication, and monitoring to prevent complications. For Type 1 diabetes, insulin therapy is essential since the body cannot produce insulin, and this can be administered via injections or an insulin pump. Type 2 diabetes management often begins with lifestyle modifications, including a balanced diet, regular physical activity, and weight loss, which can improve insulin sensitivity.

""Diabetes- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetes pipeline landscape is provided which includes the disease overview and Diabetes treatment guidelines. The assessment part of the report embraces, in depth Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetes R&D. The therapies under development are focused on novel approaches to treat/improve Diabetes.

Diabetes Emerging Drugs Chapters

This segment of the Diabetes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetes Emerging Drugs

• Retatrutide: Eli Lilly and Company

Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Retatrutide has a unique mechanism of action in the increasingly popular class of incretin mimetics. As a novel triple agonist, it harnesses the action of the three peptide hormones GLP-1, GIP, and GCG. Like other incretin mimetics, it is structurally similar to GIP, with alterations in the peptide backbone to increase agonist activity at the GIP, GLP-1, and GCG receptors. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetes.

• CT-388 (RG6640): F. Hoffmann-La Roche Ltd.

CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. It aims to reduce appetite and regulate blood sugar by selectively targeting and activating both receptors which integrate nutrient-derived signals to control energy homeostasis. CT-388 was designed to have potent activation of both GLP-1 and GIP receptors, but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimises receptor internalisation and consequent desensitization, which is expected to lead to prolonged pharmacological activity. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetes.

• AZD5004: Astrazeneca

AZD5004 is an investigational drug being developed by AstraZeneca as a novel, once-daily oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. it is designed for the treatment of cardiometabolic conditions such as type 2 diabetes mellitus and obesity. Unlike many existing GLP-1 therapies that are injectable peptides, AZD5004 is a non-peptide oral agent that activates GLP-1 receptors to enhance insulin secretion, improve glucose control, and promote weight loss. Early clinical and preclinical studies have shown that the drug is generally well tolerated and produces dose-dependent reductions in blood glucose and body weight, supporting its continued development in Phase II trials for obesity and related metabolic disorders. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetes.

• Brivekimig: Sanofi

Brivekimig (SAR442970) is a dual-target Nanobody® molecule inhibiting the tumor necrosis factor and OX40-ligand, key immune regulators. It is being investigated for potential uses across a range of immune-mediated diseases and inflammatory disorders. As a VHH antibody (Nanobody), it binds to and inhibits both TNF and OX40L, which reduces inflammation by preventing T-cell activation which helps in treatment of Diabetes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetes.

• MTX-101: Mozart Therapeutics

MTX-101 is a first-in-class bispecific antibody designed to modulate the immune system by activating CD8 regulatory T cells, which help suppress the autoimmune response responsible for destroying insulin-producing pancreatic beta cells. MTX-101 aims to address the root cause of the disease by restoring immune balance and potentially slowing or halting disease progression. Early findings suggest it is generally well tolerated and biologically active. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Diabetes.

• CNTY 813: Century Therapeutics

CNTY-813 is comprised of iPSC-derived beta islets engineered with Allo-Evasion™ 5.0 and designed to protect from T cell, NK cell and humoral immune rejection, with the goal of durable glycemic control without the need for systemic immunosuppression. The mechanism of action is based on transplantation of these functional β-cells, which respond to blood glucose levels by secreting insulin (glucose-stimulated insulin secretion), thereby helping normalize glycemic control. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of Diabetes.

Further product details are provided in the report……..

Diabetes: Therapeutic Assessment

This segment of the report provides insights about the different Diabetes drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetes

There are approx. 200+ key companies which are developing the therapies Diabetes. The companies which have their Diabetes drug candidates in the most advanced stage, i.e. Phase III include, Eli lilly and Company, and others.

• Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetes drugs.

Diabetes Report Insights

• Diabetes Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetes drugs?
• How many Diabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Astrazeneca
• Mozart Therapeutics
• Sanofi
• Century Therapeutics
• Dong-A ST Co., Ltd.
• Novo Nordisk A/S
• AstraZeneca
• Zealand pharma
• Sanofi
• Diamyd Medical
• Vactech
• Adocia
• Tonghua Dongbao Pharmaceutical
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
• Vivani medical Inc.
• Imcyse
• Amgen Inc.
• Vertex Pharmaceuticals Incorporated
• Oramed
• Gilead Sciences
• Cadrenal Therapeutics, Inc.
• TIXiMED
• Century Therapeutics.

Key Products

• Retatrutide
• CT-388 (RG6640)
• AZD5004
• MTX-101
• Brivekimig
• CNTY 813
• DA-2811
• Zenagamtide
• AZD5004
• Dasiglucagon
• Brivekimig
• Retogatein
• PRV-101
• THDB0206
• Aleniglipron
• NPM-119
• IMCY-0098
• Maridebart cafraglutide
• VX-880
• ORMD-0801
• GS-4571
• VLX 1005
• TIX 100
• Eloralintide
• CagriSema

Please Note: It will take 4-5 business days to complete the report upon order confirmation. Show more